Deficiency of carnitine palmitoyltransferase I

Area of Science:

• Biochemistry
• Metabolic disorders
• Genetics

Background:

• Carnitine palmitoyltransferase I (CPT I) is crucial for long-chain fatty acid oxidation, a key energy pathway.
• Defects in CPT I can lead to impaired fatty acid metabolism and potential health complications.
• Hypoketotic hypoglycemia is a condition characterized by low blood sugar and reduced ketone production.

Observation:

• Fibroblasts from a patient with hypoketotic hypoglycemia exhibited significantly reduced carnitine palmitoyltransferase I activity (approx. 10% of control).
• Palmitate oxidation in intact patient fibroblasts was markedly diminished (approx. 5% of control).
• The patient presented with seizures, severe hypoglycemia, and an inability to produce ketones during fasting.

Findings:

• The study confirms defective carnitine palmitoyltransferase I activity as the cause of the patient's metabolic derangement.
• Reduced CPT I activity directly correlates with impaired long-chain fatty acid oxidation.
• The patient's clinical presentation is consistent with a severe defect in fatty acid catabolism.

Implications:

• This finding highlights the critical role of CPT I in maintaining energy homeostasis, particularly during fasting.
• Early diagnosis and management of CPT I deficiency are essential to prevent severe neurological complications.
• Therapeutic strategies involving medium-chain triglycerides can bypass the defective CPT I pathway, restoring energy production and ketogenesis.